Welcome to our dedicated page for Autonomix Medical SEC filings (Ticker: AMIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Autonomix Medical, Inc. (NASDAQ: AMIX) SEC filings page on Stock Titan brings together the company’s registration statements, current reports, and other disclosures filed with the U.S. Securities and Exchange Commission. Autonomix is a development-stage medical device company focused on catheter-based nerve-sensing and targeted ablation technologies for conditions such as pancreatic cancer pain and potential cardiology and chronic disease applications.
Through this page, readers can access registration statements on Form S-1 and S-1/A, which describe Autonomix’s business, risk factors, capital structure, and details of securities offerings. These filings include information on the company’s status as a smaller reporting company and emerging growth company, its incorporation in Delaware, and its listing of common stock on Nasdaq under the symbol AMIX. They also provide context on warrants, stock plans, license agreements, and other material contracts referenced in the exhibits.
Investors can also review current reports on Form 8-K that Autonomix files to report material events. Examples include securities purchase agreements for private placements of common stock and warrants, at-the-market issuance sales agreements with investment banks, and a purchase agreement with an institutional investor committing to buy shares of common stock over time, subject to conditions. These 8-K filings outline terms such as exercise prices, beneficial ownership limits, use of proceeds for working capital and general corporate purposes, and restrictions on additional equity transactions.
Stock Titan’s platform adds AI-powered summaries that help explain the key points in lengthy filings, such as how warrant structures work, what an at-the-market agreement allows, or how a purchase agreement with an institutional investor may affect potential dilution. Users can quickly identify where Autonomix discusses its development-stage medical device business, nerve-sensing and ablation platform, equity financing arrangements, and governance matters, without reading every line of the underlying documents.
In addition to S-1 and 8-K filings, this page links to other SEC documents referenced by Autonomix, such as shelf registration statements, stock plans, and license agreements. For those tracking AMIX, the filings page offers real-time access to new submissions from EDGAR, along with structured views of items like unregistered sales of equity securities, at-the-market program changes, and material definitive agreements.
Autonomix Medical director Lori Bisson reported changes to her derivative holdings in a Form 4. The filing discloses transactions involving two option grants with exercise prices of $26.56 and $40, covering 18,862 and 46,680 underlying shares respectively. The $26.56 option was cancelled by mutual agreement and the reporting person received no consideration for that cancellation. Both option amounts were revised to reflect a 1-for-20 reverse stock split. The filing shows direct beneficial ownership following the transactions of 47,930 and 1,250 derivative securities.
Trent N. Smith, identified as the Chief Financial Officer of Autonomix Medical, Inc. (AMIX), reported derivative transactions dated 08/11/2025 involving company stock options. The filing lists an option with a $26.56 exercise price tied to 11,405 underlying shares and an option with a $40.00 exercise price tied to 21,250 underlying shares. The filing’s footnotes state the $26.56 option was cancelled by mutual agreement and that the reporting person received an additional three months' severance as consideration for that cancellation. The footnotes also note the reported share amounts and exercise prices were revised to reflect a 1-for-20 reverse stock split completed on October 25, 2024. Ownership is reported in a direct form.
Autonomix Medical, Inc. is a pre-revenue, clinical-stage medical device company advancing a catheter-based sensing and radiofrequency ablation platform. For the three months ended June 30, 2025, the company reported a net loss of $3.3 million (versus $2.7 million a year earlier), research and development expense of $1.6 million (up 67%), and general and administrative expense of $1.8 million. Cash totaled $8.6 million with working capital of $7.0 million as of June 30, 2025. Weighted average shares outstanding were 3,105,156, producing loss per share of $1.07. The company completed a 1-for-20 reverse stock split and raised financing including a November 2024 offering (gross ~$10.0 million; net proceeds ~$9.0 million) and ATM sales of 1,304,260 shares for net proceeds of ~$2.1 million.
The company reported positive early clinical results from its PoC 1 study with mean pain reduction of 59.2% among responders, no device-related serious adverse events, initiation of PoC 2 in June 2025, two issued U.S. patents, and an FDA pre-submission meeting that framed a path toward an EFS and potential De Novo approval target in 2028. Management discloses substantial doubt about going concern, estimating cash resources sufficient only into, but not beyond, the second calendar quarter of 2026 and forecasting an additional financing need of approximately $32–40 million to reach commercialization.